Hypothesis

Senescent cells act as metabolic hostage negotiators whose low α‑ketoglutarate (αKG) and NAD+ levels create a detectable systemic signature that predicts whether tissue will undergo regenerative repair or fibrotic degeneration. We propose that continuous glucose monitoring (CGM) derived glycemic variability, when combined with circulating αKG and NAD+/NADH ratios, can stratify patients into those who will benefit from senolytic clearance versus those who require senescence‑preserving interventions.

Mechanistic reasoning

• Senescent fibroblasts exhibit >30% reduced ATP and ~60% lower αKG relative to proliferating cells, limiting TCA cycle flux and promoting a pseudo‑hypoxic state that drives SASP secretion via HIF‑1α stabilization [4].
• Low αKG also inhibits αKG‑dependent dioxygenases (e.g., TET, JmjC domain histone demethylases), leading to hypermethylation of pro‑regenerative genes and a shift toward a pro‑inflammatory SASP profile [2][3].
• The NAD+/NADH ratio decline further reduces sirtuin activity, decreasing deacetylation of NF‑κB and amplifying IL‑6/IL‑8 release, which in turn alters systemic glucose handling through hepatic gluconeogenesis and muscle insulin resistance.
• Additionally, the senescence‑associated increase in succinate can stabilize HIF‑1α independently of oxygen, further coupling metabolic rewiring to inflammatory cytokine production [5].
• Elevated succinate also acts as an extracellular signal through its receptor SUCNR1 on immune cells, exacerbating local inflammation and contributing to systemic insulin resistance [6].
• It's likely that hepatic glucose output influences interstitial glucose fluctuations measured by CGM, so we predict that individuals with elevated senescent burden will show increased glycemic variability (higher CGM‑derived SD and mean amplitude of glycemic excursions) concurrent with low plasma αKG and NAD+/NADH.

Testable predictions

1. In a cohort of patients with acute wounds, baseline CGM variability will inversely correlate with tissue αKG levels (measured via microdialysis) and positively correlate with SASP IL‑6 concentrations; high variability will predict delayed healing unless senescent cells are transiently preserved.
2. In diabetic ulcer patients, administering a NAD+ booster (e.g., NR) will raise the NAD+/NADH ratio in senescent fibroblasts, reduce SASP IL‑6/IL‑8, lower CGM variability, and accelerate healing only when senescent cells are not cleared concurrently with senolytics.
3. Genetic inhibition of αKG‑dependent dioxygenases in fibroblasts will reproduce the senescent metabolic signature, increase SASP, and elevate CGM variability in mice; rescuing αKG levels with cell‑permeable dimethyl‑αKG will normalize variability and improve wound closure.

Falsifiability If CGM‑derived glycemic variability shows no association with plasma αKG, NAD+/NADH, or SASP markers across wound types, or if modulating NAD+ or αKG fails to alter variability and healing outcomes as predicted, the hypothesis is refuted.

Implications Linking a wearable glucose metric to the metabolic state of senescent cells offers a non‑invasive window to time senolytic or senostatic interventions, preserving the hostage‑negotiator role when beneficial and disabling it when pathological.